What is Clopidogrel 75 mg tablet used for?

In the pharmaceutical industry, Clopidogrel Bisulphate 75 mg is the gold-standard P2Y12 platelet inhibitorAs a pharmacist, you recognize this as a critical “anti-aggregant” used to prevent atherothrombotic events. Unlike anticoagulants (like Warfarin), which target clotting factors, Clopidogrel specifically targets the “stickiness” of platelets.

Primary Clinical Uses

  • Recent Myocardial Infarction (Heart Attack): To reduce the rate of a recurrent stroke or heart attack.

  • Acute Coronary Syndrome (ACS): Used in patients with unstable angina or NSTEMI, often in combination with Aspirin (Dual Antiplatelet Therapy – DAPT).

  • Recent Ischemic Stroke: Indicated for patients with a history of recent stroke to prevent further cerebrovascular events.

  • Peripheral Arterial Disease (PAD): Used to reduce the risk of cardiovascular death in patients with established PAD (claudication).

  • Stent Maintenance: Essential post-stenting to prevent “stent thrombosis,” a life-threatening complication where a clot forms on the newly placed hardware.

Mechanism of Action

Clopidogrel is a prodrug that requires hepatic bioactivation via the CYP450 enzyme system (primarily CYP2C19).

It works by irreversibly binding to the P2Y12 adenosine diphosphate (ADP) receptor on the platelet surface. By blocking this receptor, it prevents the activation of the GPIIb/IIIa receptor complex, which is necessary for platelets to bind to fibrinogen and stick to each other. Because the binding is irreversible, the affected platelets are inhibited for the remainder of their lifespan (approx. 7–10 days).

The Manufacturer’s Perspective: Formulation & Export

From a manufacturing and global trade standpoint, Clopidogrel 75 mg is a high-volume essential:

  • Polymorphism Control: Clopidogrel Bisulphate exists in multiple polymorphic forms (Form I and Form II). As a WHO-GMP manufacturer, we strictly control the crystallization process to ensure we use the more stable Form II, which provides consistent bioavailability and shelf-life.

  • Stability & Sensitivity: The API is highly sensitive to moisture and light. We utilize Alu-Alu blister packaging to ensure the product remains stable for 36 months, even in the harsh conditions of Zone IVb export markets (Africa, Southeast Asia).

  • Bioequivalence (BE): This is a competitive market. Our Mumbai-based facility provides comprehensive BE studies and CTD/eCTD Dossiers to prove our generic version is bioequivalent to the innovator (Plavix), facilitating smooth international registration.

  • Drug Interactions: We provide technical data regarding the “CYP2C19” interaction, warning against the co-administration of Proton Pump Inhibitors (PPIs) like Omeprazole, which can reduce Clopidogrel’s efficacy.

What is Clopidogrel 75 mg tablet used for?

In the pharmaceutical industry, Clopidogrel 75 mg is a standard-of-care thienopyridine-class antiplatelet agent. As a pharmacist, I characterize Clopidogrel as a vital “blood thinner” (though technically an anti-aggregant) used to prevent atherothrombotic events in patients with high-risk cardiovascular profiles.

Primary Clinical Uses

  • Acute Coronary Syndrome (ACS): Used to manage patients with unstable angina or NSTEMI (Non-ST elevation myocardial infarction), often in combination with Aspirin (Dual Antiplatelet Therapy or DAPT).

  • Recent Myocardial Infarction (MI): Prescribed to prevent a second heart attack in patients who have recently suffered one.

  • Recent Ischemic Stroke: Used to reduce the risk of a recurrent stroke in patients with a history of ischemic cerebrovascular events.

  • Peripheral Arterial Disease (PAD): Indicated to improve circulation and reduce the risk of vascular complications in patients with established PAD.

  • Post-Stent Implantation: Critical for preventing stent thrombosis after the placement of coronary stents.

Mechanism of Action

Clopidogrel is a prodrug that requires hepatic bioactivation by the cytochrome P450 system (primarily CYP2C19).

Irreversible Inhibition: Once activated, it selectively and irreversibly binds to the P2Y12 subtype of ADP receptors on the surface of platelets.

Prevention of Aggregation: By blocking these receptors, it prevents the activation of the GPIIb/IIIa receptor complex, which is necessary for platelets to bind to fibrinogen and to each other.

Life of the Platelet: Because the binding is irreversible, the affected platelets are inhibited for the remainder of their lifespan (approximately 7–10 days).

The Manufacturer’s Perspective: Formulation & Export

From a manufacturing and global trade standpoint, Clopidogrel 75 mg is a high-volume essential medicine:

  • Polymorphism Control: Clopidogrel Bisulphate exists in different polymorphic forms (Form I and Form II). As a WHO-GMP manufacturer, we strictly control the crystallization process to ensure we use the most stable and bioavailable form.

  • Moisture Sensitivity: Clopidogrel is highly susceptible to hydrolysis. We utilize Alu-Alu blister packaging almost exclusively to ensure a stable 24-month shelf life, especially for export to Zone IVb climates (Africa, Southeast Asia).

  • Bioequivalence: Since this is a life-saving medication, we conduct rigorous comparative dissolution and bioequivalence studies against the innovator (Plavix) to ensure therapeutic equivalence.

  • Global B2B Supply: Clopidogrel is a staple for hospital tenders and chronic care pharmacies. Our Mumbai hub provides complete CTD/eCTD Dossiers to facilitate registration in international markets.

Add to cart